Rationale Cariprazine is a novel antipsychotic drug candidate that exhibits high selectivity and affinity to dopamine D 3 and D 2 receptors and moderate affinity to serotonin 5-HT 1A receptors. Targeting receptors other than D 2 may provide a therapeutic benefit for both positive and negative symptoms associated with schizophrenia. Positron emission tomography (PET) can be used as a tool in drug development to assess the in vivo distribution and pharmacological properties of a drug. Objectives The objective of this study was to determine dopamine D 2 /D 3 and serotonin 5-HT 1A receptor occupancy in monkey brain after the administration of cariprazine. Methods We examined three monkeys using the following PET radioligands: receptors). During each experimental day, the first PET measurement was a baseline study, the second after a low dose of cariprazine, and the third after the administration of a high dose.
Introduction
Antipsychotic drugs have been shown to be beneficial for the treatment of schizophrenia. Antagonism at the dopamine D 2 receptor is considered an essential component of their mechanism of action (Creese et al. 1976; Seeman et al. 1975) . Antipsychotic drugs acting at other receptor targets, such as the D 3 receptor, may provide a promising target due to the receptor's anatomical localization and pharmacological properties (Sokoloff et al. 2006) . Early in vitro studies have shown that the D 3 receptor is concentrated in limbic areas (e.g., nucleus accumbens), whereas in vivo studies in primate and human brain using [ 11 C]-(+)-PHNO have extended the earlier in vitro localization studies now showing high concentrations of the D 3 receptor in areas such as globus pallidus<substantia nigra<ventral striatum< thalamus (Searle et al. 2010; Rabiner et al. 2009; Tziortzi et al. 2011 ). Thus, the receptor's anatomical localization suggests that the receptors may be involved in modulating memory function, speech, and focused attention in schizophrenia (Sokoloff et al. 1990; Suzuki et al. 1998) . Studies in mice lacking the dopamine D 3 receptor aide in understanding the functional role of this receptor subtype, which may well be involved in the regulation of anxiety (Steiner et al. 1997) , increased locomotor activity and rearing behavior (Accili and Fuchs 1996) , and regulation of dopamine levels (Le Foll et al. 2005) . In addition, a twofold elevation in D 3 receptor expression has been found in postmortem tissue of schizophrenic patients (Gurevich et al. 1997) . Thus, antipsychotic drugs acting selectively on the D 3 receptor may provide an effective treatment for patients with schizophrenia.
Cariprazine is a novel antipsychotic drug candidate that exhibits high affinity for the D 3 (K i =0.085 nM) and D 2 (K i =0.49 nM) receptors, and moderate affinity for the 5-HT 1A receptor (K i =2.6 nM, Table 1 ; Kiss et al. 2010 ). Cariprazine was evaluated in multiple in vitro and in vivo functional assays and demonstrated antagonist-partial agonist properties at D 2 and D 3 receptors (Kiss et al. 2010 ). In addition, rodent models predicting antipsychotic-like activity such as conditioned avoidance response and inhibition of amphetamine-induced hypermotility confirmed that cariprazine does possess antipsychotic potential while devoid of cataleptogenic effect in comparison with reference antipsychotic drugs (Gyertyán et al. 2006) . The affinity of cariprazine for the D 3 receptor is significantly higher than that of marketed antipsychotic drugs and may provide additional therapeutic benefits compared with more D 2 -selective agents (Schotte et al. 1996; Millan et al. 1999) .
Positron emission tomography (PET) can be used as a tool in drug development to assess the in vivo distribution and pharmacological properties of a drug (Lee and Farde 2006; Halldin et al. 2001; Wong et al. 2009; Hargreaves 2008) . One approach is to measure the degree to which administration of a new drug candidate (such as cariprazine) competes with the specific binding of a characterized PET radioligand for the receptor target of interest (e.g., dopamine D 2 /D 3 receptors). The effects of a new drug candidate are related to the percentage of receptor sites occupied by the drug and receptor occupancy reflected as the percent change in the PET outcome measure determined under the drug treatment condition compared with that under baseline measures. Another approach would be to extrapolate the in vitro determination of intrinsic activity using receptor binding assays to the in vivo situation of PET receptor occupancy studies (Lahti et al. 1992; Sibley and Creese 1983) . Receptor occupancy studies utilizing a dual radioligand approach (i.e., radiolabeled agonist and radiolabeled antagonist) may provide a functional profile of the new drug candidate's intrinsic activities. For example, if the candidate new drug has an antagonist profile, a comparison of the agonist/antagonist radioligand ratio of receptor occupancy would be~1.0, whereas if the candidate new drug has an agonist profile, this ratio would result in a higher value. In the current study, we used PET imaging with an agonist and antagonist radioligand to determine the in vivo potency of cariprazine and assess its intrinsic activity as an agonist vs. as an antagonist.
The aim of the present study was to determine whether cariprazine occupies dopamine D 2 /D 3 and serotonin 5-HT 1A receptors in monkey brain. We used both antagonist ([ 11 11 C]WAY-100635 were prepared as described previously (Langer et al. 1999; Finnema et al. 2005; Pike et al. 1995 Kiss et al. (2010) b Schotte et al. (1996) c Millan et al. (1999) d Skinbjerg et al. (2009) e Johansson et al. (1997) 100635 (52-58 MBq, n=6) in three monkeys, PET measurements were acquired for 93 min in 20 frames, with frames of 3×1 min, 4×3 min, and the remaining frames of 6 min. PET measurements were acquired in threedimensional mode with the Siemens ECAT Exact HR 47 (Wienhard et al. 1994) . Before radioligand injection, a 10-min transmission measurement for attenuation correction was collected using a 68 Ge line source. The monkeys participated in three consecutive PET measurements per experimental day. The first PET measurement was performed at baseline conditions, the second after a low dose (1-5 μg/kg) of cariprazine, and the third after the administration of a high dose (30-300 μg/kg). Cariprazine was injected intravenously over 30 s, approximately 15 min prior to radioligand injection. The study timeline for PET measurements, administration of study drug, and venous blood sampling is shown in Scheme 1. Gedeon Richter Plc. (Budapest, Hungary) provided cariprazine.
Image analysis and calculation of outcome measures
To calculate dopamine and serotonin receptor occupancy, the outcome measure was quantified with two methods, the transient equilibrium method and the two-parameter multilinear reference tissue model (MRTM2). The first outcome measure was the transient equilibrium method (Farde et al. 1992; Andree et al. 1998; Nyberg et al. 1996; Ito et al. 1998) . Briefly, the transient equilibrium method calculates the ratio of bound/free as defined as the concentration in tissue of interest (C T (t)) minus the concentration in the reference region (C REF (t)) (bound) and the total radioactivity in a reference region (C REF (t)) (free) with negligible density of D 2 /D 3 and 5-HT 1A receptors. The radioactivity in the cerebellum was used as an approximate value for free and non-specifically bound radioligand concentration, bearing in mind the negligible density of D 2 /D 3 (Hall et al. 1994 (Hall et al. , 1996 and 5-HT 1A receptors in the cerebellum (Hall et al. 1997) . The ratio bound/free obtained at the peak of specific binding timeactivity curve is assumed to represent transient equilibrium (Farde et al. 1989) . The second outcome measure we used is the two-parameter multilinear reference tissue model (Ichise et al. 2003) which fits the time-activity curves of the striatum and the cerebellum from 1 min to the end of scan (93 min).
The regions of interest were identified from images created by the two-parameter multilinear reference tissue model (Ichise et al. 2003) . This model generates two parametric images from each scanning session: One shows binding potential (BP ND ) and another shows blood flow relative to the reference region. Anatomical regions of interest were manually defined on the fused image for left and right striatum and cerebellum for dopamine D 2 /D 3 radioligands, temporal and frontal cortex (defined as forebrain), raphé nuclei, and cerebellum for the 5HT 1A radioligand. The MRTM2 model requires a priori estimation of a reference region clearance rate (k 2 ′) which was estimated using the three-parameter MRTM from the target and reference region of interest activities. All parametric imaging was performed in PMOD (Mikolajczyk et al. 1998) installed on a PC workstation. Brain uptake was expressed as a standardized uptake value (%SUV) which normalizes for injected activity and body weight.
To calculate D 2 /D 3 and 5-HT 1A receptor occupancy, the striatum, forebrain, and raphe nuclei were used as the regions of interest, respectively. Receptor occupancy was defined as the percentage change in the PET outcome measures quantified with two methods, the transient equilibrium method and the two-parameter multilinear reference tissue model. The effects of cariprazine are related to the percentage of receptor sites occupied by the drug which is reflected by the reduced receptor availability of the PET radioligands.
Receptor occupancy was operationally defined as:
Cariprazine, desmethyl-, and didesmethyl-cariprazine concentration in plasma Venous blood samples (1-2 mL) were obtained from the femoral vein at baseline before drug administration (−5 min), at 20 min after the administration of the low dose (PET 2), and at 20, 30, 60, and 105 min after the injection of the highest dose of the compound. Samples were collected into spray-dried EDTA tubes and centrifuged. The plasma samples were stored frozen at or below −70°C prior to the analysis. The plasma samples were analyzed for cariprazine and its metabolites, desmethyl-and didesmethyl-cariprazine, by a selective and sensitive LC-MS/MS method. Liquid-liquid extraction was used to isolate the compounds from the biological matrix. The extracts were subjected to reversedphase HPLC with MS/MS detection. The mass spectrometer was equipped with a Turbo IonSpray interface and operated in positive ion multiple reaction monitoring mode. Deuterated derivatives were used as internal standards. For all the three analyses, the lower limit of quantification of the method was 0.5 ng/mL using 100 μL of plasma, and the calibration curve ranged from 0.5 to 250 ng/mL.
Results

After the injection of [
11 C]raclopride or [ 11 C]MNPA, uptake of radioactivity was highest in the striatum, with lower levels in the cerebellum (Fig. 1a, b) . Administration of cariprazine (30 μg/kg) reduced the striatal uptake of both radioligands to the level of nonspecific binding compared with baseline PET measurements (Fig. 1a, b) . Cariprazine had negligible effect on the time-activity curves in the cerebellum. At doses of 5.0 and 30 μg/kg, cariprazine caused a dose-dependent dopamine D 2 /D 3 receptor occupancy of~45% and~80% for both antagonist [
11 C] raclopride and agonist radioligand [
11 C]MNPA (Figs. 2  and 3 ). Receptor occupancy of dopamine D 2 /D 3 receptors calculated using the transient equilibrium and the MRTM2 methods ranged from 5% at the lowest dose (1.0 μg/kg) to 94% at the highest dose (300 μg/kg; Fig. 3a and Table 2 ). A comparison of antagonist/agonist radioligand ratio of receptor occupancy showed a ratio of~1.0, suggesting that occupancy of D 2 /D 3 receptors by cariprazine equally displaced the agonist and antagonist radioligand.
Following injection of [carbonyl-11 C]WAY-100635, uptake of radioactivity was highest in the forebrain and raphe nuclei with lower levels in the cerebellum (Fig. 1c) . Intravenous administration of 30 μg/kg of cariprazine slightly reduced radioactivity in the raphe nuclei compared with baseline and had no effect in the forebrain. 5-HT 1A receptor occupancy could be described by a hyperbolic function, and the maximal reduction of [carbonyl-11 C]WAY-100635 binding was~30% for the raphe nuclei (Fig. 3b) .
The plasma concentrations of cariprazine increased with dose, with values ranging from <1.0 ng/mL at the lower doses (1-5 μg/kg) to 3.11-34.1 ng/mL at the higher doses (30-300 μg/kg). The concentration of desmethyl-or didesmethylcariprazine at all doses of cariprazine studied was <5 ng/mL.
Discussion
In this study, we have shown that administration of cariprazine at increasing doses resulted in a dosedependent and saturable reduction in the specific binding of The pharmacological properties of cariprazine using multiple in vitro and in vivo functional assays demonstrated antagonist-partial agonist properties at D 2 and D 3 receptors (Kiss et al. 2010) . To explore the in vivo pharmacological properties of cariprazine, we compared receptor occupancy Scheme 1 Imaging study timeline. Top boxes reflect the intravenous doses of cariprazine administered~15 min prior to PET measurement 2 or PET measurement 3. The boxes below reflect the series of PET measurements per study day. The information below the series of PET measurements refers to timing in minutes of the blood samples for estimation of the plasma concentration of cariprazine, desmethyl-, and didesmethyl-cariprazine of D 2 /D 3 receptors using a dual radioligand approach (i.e., using a radiolabeled agonist and a radiolabeled antagonist). At tracer doses, the agonist radioligand is thought to bind almost exclusively to the high-affinity state of the receptor, whereas the antagonist radioligand binds with equal affinity to both high-and low-affinity states. It has been suggested that the preference of a drug for the high-affinity state (reflected as an agonist/antagonist ratio of drug inhibition of >1) may relate to the intrinsic activity to the receptor in in vitro studies (Lahti et al. 1992) . Thus, an agonist/ antagonist radioligand receptor occupancy ratio may provide an in vivo estimation of intrinsic activity. The agonist/ antagonist receptor occupancy ratio for cariprazine was~1.0, potentially suggesting antagonistic properties. However, in a similar PET study, we showed comparable D 2 /D 3 receptor occupancy for the agonist apomorphine when comparing apomorphine's occupancy of a radiolabeled agonist and a radiolabeled antagonist (Finnema et al. 2009 ). Thus, we Squares and circles (a, b) represent radioactivity concentrations in the striatum and cerebellum, respectively. Square, triangle, and circle (c) represent radioactivity concentrations in the forebrain, raphe, and cerebellum, respectively therefore cannot exclude the (partial) agonistic properties of cariprazine.
The lack of subtype selectivity of the dopamine receptor PET radioligands used in this study for D 2 vs. D 3 receptors makes it difficult to assess the relative occupancy at these receptor subtypes. After the injection of (Tziortzi et al. 2011; Searle et al. 2010) .
The finding of the relatively low maximal 5-HT 1A receptor occupancy suggests that cariprazine could have limited pharmacological actions via this target. These PET data demonstrated an ED 50 value of 5 μg/kg at the D 2 /D 3 receptors and a five times greater dose induced only~18% occupancy at the 5-HT 1A receptor. These receptor occupancy values may be underestimated since [carbonyl-
11 C] WAY-100635 is an antagonist and binds with equal affinity to the high-and low-affinity states of the receptor, as described earlier. If cariprazine acts as a partial agonist, it may bind preferentially to a subpopulation of these receptors that are in the high-affinity state. However, the 5-HT 1A full agonist 8-OH-DPAT and partial agonist buspirone have been shown to displace all of the antagonist radioligand [carbonyl-11 C]WAY-100635 binding in monkey brain (Mathis et al. 1994; Farde et al. 1997) . The primary CNS actions of cariprazine are therefore related to the D 3 and D 2 receptors, with minimal 5-HT 1A -related effects at therapeutic dose levels.
Several methodological considerations should be taken into account when interpreting the results of the present PET study. (1) The dual radioligand approach using the agonist and antagonist D 2 /D 3 receptor radioligand used a small sample size, and the reliability of this approach has to be confirmed in larger samples. (2) The small ROI for the raphe nuclei may have caused noisy time-activity curves, and the resolution of PET restricts our ability to quantify accurately the BP ND in this area. (3) Autoradiographic studies with [carbonyl-
11 C]WAY-100635 have found the cerebellum almost devoid of 5-HT 1A receptors (Hall et al. 1997) , with the exception of the vermis that contains a moderate density of sites. As described in detail by Parsey et al. (2005) , we excluded the vermis from the cerebellar region of interest since this method allows for a more accurate estimation of the reference region. (4) Ketamine and xylazine were used to induce and maintain anesthesia and may have affected radioligand binding. Ketamine administered at greater doses has been found to reduce [ 11 C]raclopride binding in monkey striatum (Tsukada et al. 2000) , whereas several studies in humans at lower doses have found no change in [ 11 C]raclopride striatal binding (Aalto et al. 2002; Kegeles et al. 2002) . In addition, ketamine can inhibit serotonin uptake and increase the levels of serotonin in the rat brain (Martin et al. 1982 ). Thus, ketamine may have some effect on radioligand binding in these PET studies.
We applied two methods to calculate the binding potential and to quantify receptor occupancy. The first approach estimated the binding potential by using the transient equilibrium method that has been applied extensively to both pre-clinical monkey and human clinical PET studies (Farde et al. 1988 (Farde et al. , 2000 . The second method to calculate binding potential was estimated with MRTM2; this model incorporates two strategies to improve parameter estimation at the voxel noise level: (1) The number of parameters are reduced from three to two by fixing k 2 ′ to a value estimated from the selected regions of interest and (2) rapid linear least squares estimation algorithm allows faster computation (Ichise et al. 2003) . In addition, MRTM is identical to SRTM reference tissue model when MRTM t* is set near zero. However, the clear advantage of MRTM2 is that this reference tissue model can be used for radioligands with two tissue compartmental model kinetics (Ichise et al. 2003) . The D 2 /D 3 receptor BP ND and receptor occupancy values were similar between the two quantitative methods applied in these studies ( 
